Systematic Evaluation of Promising Clinical Trials-Gene Silencing for the Treatment of Glioblastoma

Basit Öğe Kaydı
dc.authoridYILMAZ, Ibrahim/0000-0003-2003-6337
dc.authoridyasar sirin, duygu/0000-0002-1224-442X
dc.authoridYilmaz, Ibrahim/0000-0003-1503-4046
dc.contributor.authorKaraarslan, Numan
dc.contributor.authorYılmaz, İbrahim
dc.contributor.authorÖzbek, Hanefi
dc.contributor.authorÇalışkan, Tezcan
dc.contributor.authorTopuk, Savas
dc.contributor.authorYasar Sirin, Duygu
dc.contributor.authorAteş, Özkan
dc.date.accessioned2025-03-26T17:35:08Z
dc.date.available2025-03-26T17:35:08Z
dc.date.issued2019
dc.departmentİstanbul Esenyurt Üniversitesi
dc.description.abstractAIM: To systematically investigate the role of artificial small interfering RNA (SiRNA) molecules in glioblastoma treatment and to give a detailed overview of the literature concerning studies performed in this field worldwide in the last 31 years. MATERIAL and METHODS: Articles about clinical trials conducted between December 1, 1949 and November 8, 2017, were identified from the Cochrane Collaboration, the Cochrane Library, Ovid MEDLINE, ProQuest, the National Library of Medicine, and PubMed electronic databases, using the terms post transcriptional gene silencing, small interfering RNA, siRNA, and glioblastoma, either individually or combined (OR and AND), without language and country restrictions. Articles that met the examination criteria were included in the study. After descriptive statistical evaluation, the results were reported in frequency (%). RESULTS: After scanning 2.752 articles, five articles were found that met the research criteria. Examination of full texts of the five identified articles provided no sufficient evidence for research conducted with regard to the use of gene silencing via siRNAs in glioblastoma treatment. CONCLUSION: To be able to evaluate the clinical use of siRNAs, there is an urgent need for in vivo studies and for trials with randomized, controlled, and clinical designs that provide long-term functional outcomes.
dc.identifier.doi10.5137/1019-5149.JTN.22467-18.3
dc.identifier.endpage334
dc.identifier.issn1019-5149
dc.identifier.issue3
dc.identifier.pmid29694664
dc.identifier.scopus2-s2.0-85065877677
dc.identifier.scopusqualityQ3
dc.identifier.startpage328
dc.identifier.trdizinid355848
dc.identifier.urihttps://doi.org/10.5137/1019-5149.JTN.22467-18.3
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/355848
dc.identifier.urihttps://hdl.handle.net/20.500.14704/1059
dc.identifier.volume29
dc.identifier.wosWOS:000466983900003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Neurosurgical Soc
dc.relation.ispartofTurkish Neurosurgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250326
dc.subjectBrain tumor; Glioblastoma; Posttranscriptional gene silencing; siRNA vector
dc.titleSystematic Evaluation of Promising Clinical Trials-Gene Silencing for the Treatment of Glioblastoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Sağlık Bilimleri Fakültesi Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu